Pallidal versus subthalamic deep-brain stimulation for meige syndrome: a retrospective study
| Autor: | Zhi Liu, Hu Ding, Ke Xu, Ruen Liu, Jiayu Liu, Zeyu Miao, Dongliang Wang, Jia Ouyang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Deep brain stimulation Hamilton Anxiety Rating Scale medicine.medical_treatment Science Deep Brain Stimulation Globus Pallidus Article Pittsburgh Sleep Quality Index 03 medical and health sciences 0302 clinical medicine Subthalamic Nucleus medicine Humans 030212 general & internal medicine Neurostimulation Aged Retrospective Studies Dystonia Multidisciplinary business.industry Meige Syndrome Middle Aged medicine.disease Subthalamic nucleus Neurology Physical therapy Anxiety Medicine Female medicine.symptom business 030217 neurology & neurosurgery Neurological disorders |
| Zdroj: | Scientific Reports Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021) |
| ISSN: | 2045-2322 |
| Popis: | Deep-brain stimulation (DBS) is an effective treatment for patients with Meige syndrome. The globus pallidus interna (GPi) and the subthalamic nucleus (STN) are accepted targets for this treatment. We compared 12-month outcomes for patients who had undergone bilateral stimulation of the GPi or STN. Forty-two Asian patients with primary Meige syndrome who underwent GPi or STN neurostimulation were recruited between September 2017 and September 2019 at the Department of Neurosurgery, Peking University People’s Hospital. The primary outcome was the change in motor function, including the Burke–Fahn–Marsden Dystonia Rating Scale movement (BFMDRS-M) and disability subscale (BFMDRS-D) at 3 days before DBS (baseline) surgery and 1, 3, 6, and 12 months after surgery. Secondary outcomes included health-related quality of life, sleep quality status, depression severity, and anxiety severity at 3 days before and 12 months after DBS surgery. Adverse events during the 12 months were also recorded. Changes in BFMDRS-M and BFMDRS-D scores at 1, 3, 6, and 12 months with DBS and without medication did not significantly differ based on the stimulation target. There were also no significant differences in the changes in health-related quality of life (36-Item Short-Form General Health Survey) and sleep quality status (Pittsburgh Sleep Quality Index) at 12 months. However, there were larger improvements in the STN than the GPi group in mean score changes on the 17-item Hamilton depression rating scale (− 3.38 vs. − 0.33 points; P = 0.014) and 14-item Hamilton anxiety rating scale (− 3.43 vs. − 0.19 points; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|